A recent study suggests that despite Novo Nordisk A/S’s (NYSE:NVO) high monthly charge of close to $1,000 for its blockbuster diabetes drug Ozempic (semaglutide) in the U.S., it could be produced for less than $5 a month.
The study, conducted by researchers at Yale University, King’s College Hospital in London, and Doctors Without Borders, sheds light on the escalating costs of top-selling diabetes treatments, including Ozempic and similar GLP-1s used for weight loss.
The soaring demand for these medications contrasts with more insurers dropping coverage due to their high prices, leaving many patients unable to afford them.
This ...